BR103354
BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.
For research use only. We do not sell to patients.
- CAS No.: 2505339-87-5
- Formula: C19H15F2N5O2S
- Molecular Weight:415.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GLUT1 |
In Vitro
BR103354 (0.03 nM-100 μM; 60 min at 37°C) potently and selectively inhibits purified human FAP with an IC50 of 14 nM[1].
BR103354 inhibits serum FAP activity across mouse, cynomolgus monkey, and human samples with similar potency, with IC50 values ranging from 27 to 31 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Differentiated 3T3/L1 adipocytes
-
Concentration:5 μM
-
Incubation Time:2 h (pre-incubation of hFGF21 with FAP; then added to cells)
-
Result:Restored phosphorylated ERK and Glut1 levels that had been reduced by co-treatment of hFGF21 with FAP, matching levels observed with hFGF21 treatment alone.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | Bioavailability |
|---|---|---|---|---|---|---|
| Mice[1] | 1 mg/kg | p.o. | 0.5 h | 2.3 μg/mL | 1.2 h | 48.4 % |
| Mice[1] | 5 mg/kg | p.o. | 0.5 h | 7.2 μg/mL | 1.1 h | 48.4 % |
| Mice[1] | 10 mg/kg | p.o. | 0.5 h | 19.2 μg/mL | 1.2 h | 48.4 % |
| Mice[1] | 100 mg/kg | p.o. | 1 h | 66.0 μg/mL | 4.0 h | 48.4 % |
| Mice[1] | 200 mg/kg | p.o. | 1 h | 122.5 μg/mL | 3.8 h | 48.4 % |
| Rat[1] | 10 mg/kg | p.o. | 1.1 h | 4.4 μg/mL | 3.5 h | / |
| Monkey[1] | 10 mg/kg | i.n. | 2.3 h | 0.42 μg/mL | 1.3 h | / |
| Monkey[1] | 30 mg/kg | i.n. | 2.3 h | 2.0 μg/mL | 2.8 h | / |
In Vivo
BR103354 (20-50 mg/kg; p.o.; once daily; for 4 consecutive weeks) reduces non-fasting blood glucose levels in ob/ob mice, inhibits FAP activity by ≥80%, increases serum FGF21 levels by approximately 1.4-fold, and simultaneously improves their insulin resistance, glucose tolerance, and hepatic steatosis[1].
BR103354 (50 mg/kg; intranasal administration) inhibits FAP activity by 65%-83% and increases the level of intact FGF21 in normal cynomolgus monkeys by 1.5-3.5 folds[1].
BR103354 (10-30 mg/kg; p.o.; once daily; for 10 consecutive weeks) inhibits FAP activity, increases serum FGF21 levels by 1.5-1.9 folds, reduces levels of hepatic enzymes and metabolic biomarkers, and ameliorates hepatic steatosis and fibrosis in CDAHFD-induced NASH mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ob/ob (8-week-old male; spontaneous obese, diabetic model)[1]
-
Dosage:20 mg/kg; 50 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced average nonfasting blood glucose to 178 mg/dL (20 mg/kg group) and 154 mg/dL (50 mg/kg group) at 3 hours post-administration.
Decreased blood glucose AUC by 40-45% relative to control.
Inhibited FAP activity by more than 70% at 1 hour post-administration, with inhibition maintained up to 9 hours.
Elevated plasma intact hFGF21 levels until 3 hours post-administration, then dropped below 10 ng/mL by 6 hours.
-
Animal Model:ob/ob (8-week-old male; spontaneous obese, diabetic model)[1]
-
Dosage:20 mg/kg; 50 mg/kg
-
Administration:p.o.; once daily; 4 weeks
-
Result:Significantly reduced nonfasting blood glucose levels starting at week 2 (P<0.01) and further reduced at week 3 (P<0.001) relative to vehicle.
Inhibited FAP activity by at least 80% at week 4 relative to vehicle.
Increased serum total FGF21 levels by approximately 1.4-fold at week 4.
Showed significantly improved glucose tolerance (reduced OGTT AUC) in the 50 mg/kg group.
Significantly reduced fasting body weight, liver weight, fasting blood glucose, insulin levels, and HOMA-IR relative to vehicle.
Significantly reduced serum ALT, AST, and total cholesterol levels; serum TG and NEFA levels were unaltered.
Decreased liver TG content, with reduced Oil Red O stained area relative to vehicle.
Reduced mRNA expression of lipogenesis/steatosis-related genes, and increased fatty acid oxidation-related genes (MCAD, PPARα) in liver.
Elevated white adipose tissue adiponectin mRNA expression.
Increased ERK phosphorylation in white adipose tissue relative to vehicle.
-
Animal Model:C57BL/6J (5-week-old male; NASH induced by CDAHFD feeding for 4 weeks prior to treatment)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; once daily; 10 weeks
-
Result:Inhibited FAP activity in a dose-dependent manner relative to vehicle.
Increased serum FGF21 levels by 1.5-1.9-fold in treatment groups.
Reduced plasma ALT, AST, total cholesterol, TG, and glucose levels relative to vehicle.
Significantly reduced steatosis scores and Picrosirius red staining (fibrosis) relative to vehicle.
Chemical Information
-
CAS No. 2505339-87-5
-
Molecular Weight 415.42
-
Formula C19H15F2N5O2S
-
SMILES
O=C(C1=CSC(CC2=CC=C(C=C2)C#N)=N1)NCC(N3[C@@H](CC(F)(C3)F)C#N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)